The authors regret there were mistakes in some graphics for the subpopulation with BRAF mutated tumors in above publication. These mistakes were found in Figure 2C (small BRAF graphic), Figure 2D (only BRAF) and Figure 4 (BRAF V600E MUT and BRAF non-V600E MUT subgraphic).
To support these corrections, the Authors also note that the following section of text require some updates:
In Section 3.8. Association of KRAS, BRAF and SMAD4 SNVs, TMB-H and MSI-H with CMSs, page 254 of the printed paper
- Combined NGS and CMS data were available for 349 of 373 patients (93.6%). KRAS- and BRAF V600E-MUT tumours were mainly classified as CMS2 and 4. CMS4 was detected in 6 of 11 (54.5%) BRAF non-V600E-MUT tumours. Eight, 10 and 9 SMAD4-MUT tumours were classified as CMS1, CMS2 and CMS4, respectively, and CMS3 was detected once. Eight of 10 MSI-H tumours (80.0%) were associated with CMS1, and one tumour was associated with CMS3 and CMS4. TMB-H tumours were enriched by CMS1, followed by CMS2, CMS4 and CMS3 (Fig. 4).
Should be corrected to
- Combined NGS and CMS data were available for 349 of 373 patients (93.6%). KRAS-MUT tumours were mainly classified as CMS2 and 4, and BRAF V600E-MUT CMS1 (75.0%), respectively. CMS2 was detected in 4 of 11 (36.3%) BRAF non- V600E-MUT tumours. Eight, 10 and 9 SMAD4-MUT tumours were classified as CMS1, CMS2 and CMS4, respectively, and CMS3 was detected once. Eight of 10 MSI-H tumours (80.0%) were associated with CMS1, and one tumour was associated with CMS3 and CMS4. TMB-H tumours were enriched by CMS1, followed by CMS2, CMS4 and CMS3 (Fig. 4).
Furthermore, in the Discussion section, page 256, the following text
- Eventually, we investigated the enrichment of relevant alterations in the previously reported mRNA expression-based CMSs (CMS1: immune, CMS2: canonical; CMS3: metabolic; CMS4: mesenchymal) [7]. While we confirmed enrichment of MSI-H, TMB-H and BRAF V600E-MUT tumours in CMS1 [7e9], BRAF non-V600E-MUT tumours were associated with CMS4, indicating again the possibility of a distinct subgroup.
Should be corrected to
- Eventually, we investigated the enrichment of relevant alterations in the previously reported mRNA expression-based CMSs (CMS1: immune, CMS2: canonical; CMS3: metabolic; CMS4: mesenchymal) [7]. While we confirmed enrichment of MSI-H, TMB-H and BRAF V600E-MUT tumours in CMS1 [7e9], BRAF non-V600E-MUT tumours were associated with CMS2, indicating again the possibility of a distinct subgroup.
The outcome results and survival curves are not affected. The corrected figures are given here.
The authors would like to apologise for any inconvenience caused.
Article info
Publication history
Published online: May 13, 2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
00178-2&id=fx1.jpg){kind=link}
00178-2&id=fx2.jpg){kind=link}